Codon Devices Signs Distribution Agreement with Open Biosystems
News Jun 26, 2007
Codon Devices, Inc., have announced that it has entered into an agreement in which Open Biosystems will distribute Codon Devices’ industry-leading gene synthesis offering in North America.
Central to its vision of Constructive Biology™, Codon Devices is driving wide-spread adoption of high-quality, low-cost synthetic genes. To date, the Company has maintained a minimum order threshold and thus access to its proprietary, industrial-scale BioFAB™ platform has been restricted to researchers with large-scale requirements.
Under the terms of the agreement, Open Biosystems will sell and distribute Codon Devices’ gene synthesis offering to researchers with needs that fall below Codon’s minimum order threshold.
The partnership will enable a wide range of new customers to utilize high-quality, low-cost gene synthesis in their research, and will greatly strengthen Codon Devices’ presence within academic, government and other non-profit institutions.
“Through aggressive investments in its BioFAB™ platform, Codon Devices has moved quickly to industrialize synthetic biology and become a world leader in gene synthesis,” said Brian Pollock, Chief Executive Officer, Open Biosystems. “We are delighted to provide our customers with a new product offering that is clearly revolutionizing how life science research is conducted.”
“We are excited to work with Open Biosystems to provide our gene synthesis offering to a wider range of customers,” said John P. Danner, President and Chief Executive Officer, Codon Devices.
“This partnership will enable more customers to access our BioFAB™ platform and harness the power of Constructive Biology™ to accelerate their research. These scientists will drive entirely new fields of academic exploration and advance groundbreaking applications in human health, agriculture, and renewable energy.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.